Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Dec 30;12(2):78-81.
doi: 10.14581/jer.22015. eCollection 2022 Dec.

The Increased Interleukin-6 Levels Can Be an Early Diagnostic Marker for New-Onset Refractory Status Epilepticus

Dong Won Kwack  1 , Dong Wook Kim  1
Affiliations
Case Reports

The Increased Interleukin-6 Levels Can Be an Early Diagnostic Marker for New-Onset Refractory Status Epilepticus

Dong Won Kwack et al. J Epilepsy Res. .

Abstract

New-onset refractory status epilepticus (NORSE) is a condition defined as the occurrence of refractory status epilepticus in patients without active epilepsy and no other acute causes of seizure. Although there is evidence that immune-mediated pathogenesis has a pivotal role in the epileptogenesis of NORSE, the diagnosis of NORSE is usually made on the clinical observation because there is no established biological marker suggesting the diagnosis of NORSE. We recently encountered a NORSE patient who was successfully treated with immunotherapy including tocilizumab, an anti-interleukin-6 (IL-6) receptor monoclonal antibody, and the markedly increased levels of serum and cerebrospinal fluid IL-6 were the only laboratory abnormality during the early treatment of the patient.

Keywords: Biomarker; Interleukin-6; Status epilepticus; Tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Electroencephalogram finding. (A) Generalized 2-Hz rhythmic delta activities with extreme delta brush (arrows) (B) low amplitude background activity with burst-suppression pattern.
Figure 2
Figure 2
Schematic illustration of clinical course with the use of anti-seizure medication (ASM) and immunotherapy. ICU, intensive care unit; IVIg, intravenous immunoglobulin.
See this image and copyright information in PMC

References

    1. Trinka E, Cock H, Hesdorffer D, et al. A definition and classification of status epilepticus--report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56:1515–23. - PubMed
    1. Gaspard N, Hirsch LJ, Sculier C, et al. New-onset refractory status epilepticus (NORSE) and febrile infection-related epilepsy syndrome (FIRES): state of the art and perspectives. Epilepsia. 2018;59:745–52. - PubMed
    1. Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85:1604–13. - PMC - PubMed
    1. Sculier C, Gaspard N. New onset refractory status epilepticus (NORSE) Seizure. 2019;68:72–8. - PubMed
    1. Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)--the potential role for immunotherapy. Epilepsy Behav. 2015;47:17–23. - PubMed

Publication types

LinkOut - more resources